The evidence for associations between genetically proxied inhibition of lipid-lowering drug targets and prostate cancer is consistent with a recently published drug target MR study [12], in which the authors applied a smaller set of genetic instruments for drug targets (11 for PCSK9, 3 for NPC1L1, and 5 for HMGCR) identified from the GWAS on LDL-c (n = 173,082) published in 2013 [72] to study the effects of lipid-lowering drugs on prostate and breast cancer risk. Here, PCSK9 is linked to prostate cancer.